U.S. Metals and Mining Stock News

Recently, analysts at Sidoti cut their Q1 2026 earnings-per-share forecast for HNI Corporation to $0.31, following earlier downgrades after a Q4 2025 earnings miss in its office furniture and hearth businesses. This shift in expectations highlights growing concern that industry headwinds and execution risks may weigh more heavily on HNI’s near-term profitability than previously thought. We’ll now examine how Sidoti’s reduced Q1 2026 EPS forecast may affect HNI’s earlier investment narrative...

AI data centers, stubborn energy costs, and heightened geopolitical risk are all pushing reliable, carbon free power to the forefront of investment thinking. Nuclear sits at the center of that discussion, with governments, utilities, and large corporates all searching for 24/7 electricity that does not depend on weather or imported fossil fuels. Our Nuclear Renaissance screener is built to help you focus on listed companies most closely aligned with this long term trend. In this article, you...

Event context and recent price performance Minimed Group (MMED) has been in focus after recent share price weakness, with the stock down 3.2% over the past week and 24.2% year to date. This has prompted fresh attention on its fundamentals. The Northridge based diabetes technology company reports annual revenue of US$2,886 and a net loss of US$211. This places its current valuation of about US$3.9b under closer scrutiny among investors. See our latest analysis for Minimed Group. With the...

Global Payments' Link2Gov unit has been selected by the IRS as a preferred digital payments provider for the 2026 tax season. The mandate covers digital tax payments, highlighting Link2Gov's role in supporting federal e-payment capabilities. This selection places NYSE:GPN directly in the middle of U.S. government efforts to modernize tax collection systems. Global Payments, through its Link2Gov unit, is focused on digital payment processing across government and enterprise clients. Being...

Tariff shift puts Tootsie Roll Industries (TR) in focus Fresh interest in candy stocks has picked up after cocoa tariffs were lifted, easing a key input cost just as seasonal demand stays supportive for Tootsie Roll Industries (TR) and its confectionery peers. See our latest analysis for Tootsie Roll Industries. At a share price of $43.73, Tootsie Roll Industries has seen momentum build recently, with a 30 day share price return of 5.65% and a year to date share price return of 27.20%,...

For investors wondering if Turning Point Brands at around US$72.16 is still offering value or if the easy gains are behind it, this article focuses squarely on what the current price might be implying. The stock has pulled back sharply in the short term, with a 15.5% decline over the last 7 days and a 21.9% decline over the last 30 days, even though the 1 year return sits at 32.8% and the 3 year return is 254.2%. Recent market attention has centered on how this performance, including a year...

In late March 2026, Golar LNG Limited filed an omnibus shelf registration covering a broad range of securities and separately began a formal review of options such as a sale, merger, asset divestitures, or corporate structure changes to accelerate its Floating Liquefied Natural Gas (FLNG) growth plans. This combination of financing flexibility and a wide-ranging review of potential transactions highlights how Golar is reassessing how best to monetize its FLNG platform, long-term contract...

BlackSky Technology (NYSE:BKSY) received a sole source, multi year US$99 million IDIQ contract from the U.S. government. The award comes from the Air Force Research Laboratory and targets advanced optical payload and next generation space intelligence capabilities. The contract focuses on large aperture optical systems and AI enabled space data tools that differ from BlackSky's existing Gen 2 and Gen 3 offerings. For readers tracking NYSE:BKSY, this contract sits at the center of the...

ArriVent BioPharma (AVBP) has drawn attention after recent trading, with the share price closing at US$24.89. Investors are weighing this clinical stage cancer drug developer’s profile against its current valuation signals. See our latest analysis for ArriVent BioPharma. That closing share price of US$24.89 comes after a 2.77% 1 day share price return and a 16.15% 7 day share price return. The 30 day share price return of 1.43% contrasts with a 19.66% 90 day share price return and a 51.58% 1...

Royalty Pharma (NasdaqGS:RPRX) has entered into a new R&D co-funding agreement with Johnson & Johnson to develop a novel autoimmune therapy. The company has also appointed a Head of Artificial Intelligence to expand the use of advanced analytics and data science across its operations. These announcements mark a shift toward greater involvement in drug development and data driven decision making. Royalty Pharma, known primarily for acquiring biopharma royalties, typically gives investors...

Regulators allowed the Hart Scott Rodino antitrust waiting period for Coterra Energy's merger with Devon Energy to expire, clearing a key hurdle. This approval means Coterra Energy (NYSE:CTRA) can move toward closing, with the company expected to become a wholly owned subsidiary of Devon. The companies currently anticipate closing the transaction in Q2 2026, subject to remaining customary conditions. Coterra Energy focuses on oil and gas exploration and production, an area where scale, cost...

Wix.com (NasdaqGS:WIX) completed a modified Dutch auction share repurchase, buying back nearly 30% of its outstanding shares. The buyback reduces Wix's share count and follows a period of increased focus on AI driven product investments. The transaction comes as some analysts lower their ratings on the stock, even as the company continues to invest in growth initiatives. Wix.com runs a global website creation and business management platform used by individuals, small businesses, and larger...

Executive change triggers fresh look at Ardent Health stock Ardent Health (ARDT) shares are in focus after the company announced that Ethan Chernin, President of Hospital Services, departed on March 24, 2026, under its executive severance plan, prompting investors to reassess leadership stability and valuation. See our latest analysis for Ardent Health. With the latest close at $8.66, Ardent Health has seen a 1 month share price return of 8.26% decline and a 1 year total shareholder return of...

Vontier Corporation recently entered into a 364-day senior unsecured term loan agreement for a US$300 million facility maturing on March 30, 2027, with interest tied to Term SOFR or a base rate plus ratings-based margins, to help repay 2026 senior unsecured notes and fund general corporate purposes. This short-term, unsecured financing underscores lenders’ confidence in Vontier’s credit profile while reshaping its near-term capital structure and liquidity position. We’ll now examine how...

Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely. See our latest analysis for Vaxcyte. The recent completion of enrollment in the OPUS-1 and OPUS-2 trials comes alongside strong momentum, with a 90 day share price return of 25.66% and a 1 year total shareholder return of 84.75%, while the latest share price stands at US$58.38. If this kind of...

In March 2026, Sun Communities’ audit committee replaced Grant Thornton with Deloitte & Touche as its independent auditor for the 2026 fiscal year, while analysts at Mizuho and BMO initiated or reiterated positive coverage highlighting the company’s manufactured housing and RV-focused business. Analysts also pointed to the potential sale of Sun’s UK Parks Holiday business and recent US$457 million of manufactured housing acquisitions as key ways to sharpen the company’s focus on core,...

Minerals Technologies Inc. recently saw analysts upgrade the stock to a Zacks Rank #2 (Buy) on the back of higher earnings estimates, while also confirming its upcoming first-quarter 2026 results release and noting planned retirements of directors Alison A. Deans and Franklin L. Feder after the May 20, 2026 annual meeting. This combination of a more optimistic earnings outlook and forthcoming board turnover highlights how expectations for operating performance are evolving alongside future...

National Presto Industries stock snapshot National Presto Industries (NPK) has quietly put up strong recent returns, with the stock up about 4.5% over the past month and roughly 32% over the past 3 months. See our latest analysis for National Presto Industries. That recent momentum sits on top of a strong longer run, with a 1 year total shareholder return of 73.12% and a 3 year total shareholder return of 117.67%. The share price is now at $141.65 after a 90 day share price return of...

AtriCure recently reported its fourth-quarter 2025 results, highlighting 15% revenue growth that underscored continued demand for its cardiac and pain management devices. The contrast between solid operating performance and more cautious analyst commentary is drawing attention to how market opinion is evolving around AtriCure’s longer-term prospects. We’ll now examine how AtriCure’s strong quarterly revenue performance interacts with shifting analyst sentiment to reshape its existing...

Insiders who purchased US$4.20m worth of Nomadar Corp. ( NASDAQ:NOMA ) shares over the past year recouped some of their...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

TOYO Co., Ltd. ( NASDAQ:TOYO ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively large...

Disc Medicine (IRON) is back in focus after the FDA issued a Complete Response Letter for its bitopertin program, triggering a 22% one day share price drop and a shareholder rights investigation. See our latest analysis for Disc Medicine. Beyond the sharp reaction to the FDA Complete Response Letter and the shareholder rights investigation, Disc Medicine’s recent 7 day share price return of 8.47% and 30 day share price return of 8.02% sit alongside a 90 day share price return of 17.59% and a...